Literature DB >> 23791814

The immune system and inflammation in breast cancer.

Xinguo Jiang1, David J Shapiro2.   

Abstract

During different stages of tumor development the immune system can either identify and destroy tumors, or promote their growth. Therapies targeting the immune system have emerged as a promising treatment modality for breast cancer, and immunotherapeutic strategies are being examined in preclinical and clinical models. However, our understanding of the complex interplay between cells of the immune system and breast cancer cells is incomplete. In this article, we review recent findings showing how the immune system plays dual host-protective and tumor-promoting roles in breast cancer initiation and progression. We then discuss estrogen receptor α (ERα)-dependent and ERα-independent mechanisms that shield breast cancers from immunosurveillance and enable breast cancer cells to evade immune cell induced apoptosis and produce an immunosuppressive tumor microenvironment. Finally, we discuss protumorigenic inflammation that is induced during tumor progression and therapy, and how inflammation promotes more aggressive phenotypes in ERα positive breast cancers.
Copyright © 2013. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Breast cancer; ER-alpha; Immunity; Immunosurveillance; Inflammation

Mesh:

Year:  2013        PMID: 23791814      PMCID: PMC4919022          DOI: 10.1016/j.mce.2013.06.003

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  150 in total

1.  Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.

Authors:  M S Shin; H S Kim; S H Lee; W S Park; S Y Kim; J Y Park; J H Lee; S K Lee; S N Lee; S S Jung; J Y Han; H Kim; J Y Lee; N J Yoo
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

2.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  A unique downstream estrogen responsive unit mediates estrogen induction of proteinase inhibitor-9, a cellular inhibitor of IL-1beta- converting enzyme (caspase 1).

Authors:  S A Krieg; A J Krieg; D J Shapiro
Journal:  Mol Endocrinol       Date:  2001-11

Review 4.  Therapeutic targeting of B7-H1 in breast cancer.

Authors:  Amal Hasan; Hazem Ghebeh; Cynthia Lehe; Rasheed Ahmad; Said Dermime
Journal:  Expert Opin Ther Targets       Date:  2011-08-28       Impact factor: 6.902

5.  Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines.

Authors:  Jonna Frasor; Aisha E Weaver; Madhumita Pradhan; Kinnari Mehta
Journal:  Endocrinology       Date:  2008-08-14       Impact factor: 4.736

Review 6.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.

Authors:  Madhuri Kakarala; Max S Wicha
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

7.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

8.  Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.

Authors:  Xiaobo Wang; Karine Belguise; Nathalie Kersual; Kathrin H Kirsch; Nora D Mineva; Florence Galtier; Dany Chalbos; Gail E Sonenshein
Journal:  Nat Cell Biol       Date:  2007-03-18       Impact factor: 28.824

9.  Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

Authors:  G E Peoples; P S Goedegebuure; R Smith; D C Linehan; I Yoshino; T J Eberlein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

10.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

View more
  74 in total

1.  Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.

Authors:  Diana C Márquez-Garbán; Gang Deng; Begonya Comin-Anduix; Alejandro J Garcia; Yanpeng Xing; Hsiao-Wang Chen; Gardenia Cheung-Lau; Nalo Hamilton; Michael E Jung; Richard J Pietras
Journal:  J Steroid Biochem Mol Biol       Date:  2019-06-19       Impact factor: 4.292

2.  Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures.

Authors:  Tal Leibovich-Rivkin; Yulia Liubomirski; Biana Bernstein; Tsipi Meshel; Adit Ben-Baruch
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Repurposing Antiestrogens for Tumor Immunotherapy.

Authors:  Thomas Welte; Xiang H-F Zhang; Jeffrey M Rosen
Journal:  Cancer Discov       Date:  2017-01       Impact factor: 39.397

Review 4.  Protective Innate Immune Variants in Racial/Ethnic Disparities of Breast and Prostate Cancer.

Authors:  LaCreis R Kidd; K Sean Kimbro; Susan T Yeyeodu
Journal:  Cancer Immunol Res       Date:  2019-09       Impact factor: 11.151

5.  Local Interleukin-2 Immunotherapy of Breast Cancer: Benefit and Risk in a Spontaneous Mouse Model.

Authors:  Svetlana G Semushina; Dmitry A Aronov; Ekaterina V Moiseeva
Journal:  Pathol Oncol Res       Date:  2018-03-06       Impact factor: 3.201

6.  Association between inflammation and cancer stem cell phenotype in breast cancer.

Authors:  Young Ju Jeong; Hoon Kyu Oh; Sung Hwan Park; Jin Gu Bong
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

Review 7.  Harnessing the immune system for the treatment of breast cancer.

Authors:  Xinguo Jiang
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

Review 8.  Gut bacteria and cancer.

Authors:  Susan E Erdman; Theofilos Poutahidis
Journal:  Biochim Biophys Acta       Date:  2015-06-04

9.  Inflammation and breast density among female Chinese immigrants: exploring variations across neighborhoods.

Authors:  Carolyn Y Fang; Brian L Egleston; Celia Byrne; Gregory S Bohr; Harsh B Pathak; Andrew K Godwin; Philip T Siu; Marilyn Tseng
Journal:  Cancer Causes Control       Date:  2019-08-07       Impact factor: 2.506

10.  Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases.

Authors:  Zhuangwei Lv; Min Liu; Jinghui Shen; Dong Xiang; Yunfeng Ma; Yanhong Ji
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.